Nanobac Pharmaceuticals Partners with Health Care Communications Firm.

TAMPA, Fla. -- Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) has enlisted The Aker Partners Inc. to implement a comprehensive national media relations program.

Nanobac is a growing pharmaceutical company in the field of medical nanotechnology. The company's focus is on developing methods to treat calcifying nanoparticles (CNPs), and by doing so, find more effective approaches to treating and preventing the cardiovascular, kidney and prostate diseases associated with them.

"Nanobac is deep into landmark medical research that we believe will redefine the way we view disease and change the way physicians approach the treatment of illnesses," said Nanobac Co-Chairman Dr. Benedict Maniscalco. "We believe utilizing the experienced professionals at The Aker Partners will not only increase the visibility of our work in the field of medical nanotechnology, but also enhance the viability of our company."

Nanotechnology is the realm of discovering and exploiting the special characteristics of materials at the atomic scale. A nanoparticle is generally considered to be anything less than 100 nanometers, or 100 billionths of a meter. If a one-meter ruler could be stretched from New York City to Los Angeles, a nanometer on that ruler would still be only the size of an aspirin.

The specialized type of medical nanotechnology being pursued by Nanobac aims to combat disease on that "nano" scale by detecting calcifying nanoparticles that straddle the 100 nanometer size line, ranging in diameter from 75 nm to more than 500 nm. Researchers believe these CNPs are the basic cause of a multitude of illnesses.

Based in Washington, D.C., The Aker Partners is a specialist in the health care industry and has broad experience in the rapidly growing field of medical nanotechnology. The agency has engineered successful communications campaigns for companies utilizing nanotechnology and is at the forefront of the effort to educate the public about the positive medical implications of the technology.

"Over the last 24 years our firm has helped more than 500 clients tell their compelling stories and communicate their accomplishments," said Aker Partners Manager Partner Colburn Aker. "The breakthroughs occurring at Nanobac are some of the most unique stories we have ever had the opportunity to help communicate."

Nanobac Pharmaceuticals:

Nanobac Pharmaceuticals Inc., based in Tampa, FL, is dedicated to the discovery and development of products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs). The company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in prostate, gall bladder and vascular disease. Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials. For details visit http://www.nanobac.com.

The Aker Partners Inc.

Since its founding in 1983, Washington-based The Aker Partners has represented more than 500 clients, providing public affairs, health care and marketing communications, plus its trademarked NetPR[R] Internet communications service. It is the nation's only Partner-Directed Communications and Marketing[R] firm and also serves as the Washington office of the Public Relations Global Network Inc.,[R] which offers clients more than 50 offices worldwide. For more information, visit www.akerpartners.com.